Management of venous thromboembolism

New England Journal of Medicine

Volumn 336, Issue 21, 1997, Pages 1506-1511

  Kearon, Clive ^a   Hirsh, Jack ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT; HEPARIN;

ANTICOAGULATION; BLEEDING; DRUG SAFETY; ELECTIVE SURGERY; HEART VALVE PROSTHESIS; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; INTRAOPERATIVE PERIOD; RISK;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN; HUMANS; INTRAOPERATIVE PERIOD; RISK; SURGICAL PROCEDURES, ELECTIVE; THROMBOEMBOLISM; WARFARIN;

EID: 0031583322     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199705223362107     Document Type: Review

References (66)

1. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108:Suppl:231S-246S.
2. Becker RC, Ansell J. Antithrombotic therapy: an abbreviated reference for clinicians. Arch Intern Med 1995;155:149-61.
3. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995;122:40-2.
4. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses: observations in 180 operations. JAMA 1978;239:738-9.
5. Francis CW, Marder VJ, Evarts CM, Yaukoolbodi S. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983;249:374-8.
6. Taberner DA, Polier L, Burslem RW, Jones JB. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. BMJ 1978;1:272-4.
7. Rustad H, Myhre E. Surgery during anticoagulant treatment: the risk of increased bleeding in patients on oral anticoagulant treatment. Acta MedScand 1963;173:115-9.
8. Francis CW, Pellegrini VD Jr, Leibert KM, et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost 1996;75:706-11.
9. Harrison L, Johnston M, Massicotte P, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-6.
10. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med 1990;112:423-8.
11. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer Lancet 1994;343:886-9.
12. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-in tensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atriaf Fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
13. Poller L, Thomson J. Evidence for "rebound" hypercoagulability after stopping anticoagulants. Lancet 1964;2:62-4.
14. Grip L, Blomback M, Schulman S. Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. Eur Heart J 1991;12:1225-33.
15. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants - a prospective study. Thromb Haemost 1994;72:222-6.
16. Valles J, Aznar J, Santos T, Villa P, Fernandez A. Platelet function in patients with chronic coronary heart disease on long-term anticoagulant therapy: effect of anticoagulant stopping. Haemostasis 1993;23:212-8.
17. Raskob GE, Durica SS, Morrissey JH, Owen WL, Comp PC. Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood 1995;85:3034-9.
18. Genewein U, Haeberli A, Straub PW, Beer IH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996;92:479-85.
19. Palareti G, Legnani C. Warfarin withdrawal: pharmacokinetic-pharmacodynamic considerations- Clin Pharmacokinet 1996;30:300-13.
20. Kluft C, Verheijen JH, Jie AF, et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor or tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985;45:605-10.
21. Flanc C, Kakkar W, Clarke MB. The detection of venous thrombosis of the legs using 125-I-labeled fibrinogen. Br J Surg 1968;55:742-7.
22. Carter CJ. The pathophysiology of venous thrombosis. Prog Cardiovasc Dis 1994;36:439-46.
23. Schulman S, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboemboHsm. N Engl J Med 1995;332:1661-5.
24. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988;208:227-40.
25. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg: is there a "high risk" group? Am J Surg 1970; 120:527-30.
26. Coon WW, Willis PW III. Recurrence of venous thromboembolism. Surgery 1973;73:823-7
27. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855-8.
28. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992;340:873-6.
29. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-11.
30. Hull RD, Carter CJ, Jay RM, et al. The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation 1983;67:901-6.
31. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960;1:1309-12.
32. Lagerstedt CJ, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;2:515-8.
33. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized trials. Arch Intern Med 1994;154:1449-57 [Erratum, Arch Intern Med 1994;154:2254.]
34. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
35. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol 1986;43:71-84.
36. Mok CK, Boey J, Wang R, et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985;72:1059-63.
37. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleed- ing complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-41.
38. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162-73.
39. Levine MN, Hirsh J, Gent M. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin, Ann Intern Med 1991;114:545-51.
40. Coon WW, Willis PW III. Hemorrhagic complications of anticoagulant therapy. Arch Intern Med 1974;133:386-92.
41. Green RM, DeWeese JA, Rob CG. Arterial embolectomy before and after the Fogarry catheter Surgery 1975;77:24-33.
42. Treiman RL, Cossman DV, Foran RF, Levin PM, Cohen JL, Wagner WH. The influence of neutralizing heparin after carotid endarterectomy on postoperative stroke and wound hematoma. J Vasc Surg 1990;12:440-6.
43. Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J 1979;97:155-8.
44. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;78:2337-43.
45. Basu D, Callus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-7
46. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-4.
47. Caplan LR, Hier DB, D'Cruz I. Cerebral embolism in the Michael Reesc Stroke Registry. Stroke 1983;14:530-6.
48. Anderson CS, Jamrozik KD, Broadhurst RJ, Stewart-Wynne EG. Predicting survival for 1 year among different subtypes of stroke. Stroke 1994; 25:1935-44.
49. Kakkar W, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery Lancet 1993;341:259-65.
50. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
51. Stein PD, Alpcrt JS, Copeland J, Dalen JE, Goldman S, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995;108:Suppl:371S-379S.
52. Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108:Suppl:276S-290S.
53. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-28.
54. Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel JP Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913-20.
55. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-6.
56. Wille-Jorgensen P, Thorup J, Fischer A, Hoist-Christensen J, Flamsholt R. Heparin with and without graded compression stockings in the prevention of thromboembolic complications of major abdominal surgery: a randomized trial. Br J Surg 1985;72:579-81.
57. Torngren S. Low dose heparin and compression stockings in the prevention of postoperative deep venous thrombosis. Br J Surg 1980;67:482-4.
58. Ramos K, Salem BI, De Pawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest 1996;109:82-5.
59. Bergqvist D. The role of vena caval interruption in patients with venous thromboembolism. Prog Cardiovasc Dis 1994;37:25-37
60. Decousus H, Efficacy and safety of permanent inferior vena cava filters and of a low molecular weight heparin (enoxaparin) in proximal deep venous thrombosis. Haemostasis 1996;26:Suppl 3:177 abstract.
61. Anderson DR, Ginsberg JS, Burrows R, Brill-Edwards P. Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb Haemost 1991;65:248-50.
62. Feinstein AR, The 'chagrin factor' and qualitative decision analysis. Arch Intern Med 1985;145:1257-9.
63. Hyams AL, Brandenburg JA, Lipsitz SR, Shapiro DW, Brennan TA. Practice guidelines and malpractice litigation: a two-way street. Ann Intern Med 1995;122:450-5.
64. McIntyre KM. Medicolegal implications of consensus statements. Chest 1995;108;Suppl:502S-505S.
65. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin; mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:Suppl:258S-275S.
66. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108:Suppl:312S-334S.